Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

Chronic Lymphocytic Leukemia Clinical Trial

Official title:

Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03939234
• Other study ID #: CLL19H1
• Secondary ID: 2018-004869-14
• Status: Completed
• Phase: Phase 2
• Start date: April 26, 2019
• Est. completion date: March 15, 2021

Study information

• Verified date: February 2022
• Source: Herlev Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is investigating the efficacy of PD-L1 and PD-L2 peptides in untreated CLL patients with unmutated IGHV gene status.

Description:

Chronic lymphocytic leukemia (CLL) is an incurable disease with the unmutated immunoglobulin heavy chain variable region (IGHV) gene status being an unfavorable prognostic marker. These patients have shorter time to first treatment which consist of toxic chemotherapy.

Programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2) are immune checkpoints hampering immune responses in many tumors including CLL. These proteins are expressed by suppressive bystander cells as well as CLL cells. Vaccinating subcutaneously with PD-L1 and PD-L2 peptides mobilises cytoxic T-cells specific towards PD-L1 and PD-L2 expressing cells. In this study we investigate if the PD-L1 and PD-L2 specific responses can overcome leukemic cells in CLL.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: March 15, 2021
• Est. primary completion date: March 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• CLL according to national guidelines (Lymphoma.dk).

• Unmutated IGHV gene according to ERIC recommendations.(25)

• No prior CLL directed treatment

• Age = 18

• Eastern cooperative oncology group (ECOG) performance status of 0 or 1

• No life-threatening conditions

• Adequate bone marrow function: Neutrophils > 1,0 x 109/l; Platelets > 100 x 109/l

• Adequate renal function: Glomeruli filtration rate (eGFR)/1,73 m2 > 50 mL/min

• Adequate liver function: Aspartate Aminotransferase < 100 U/L

• For fertile women: agreement to use contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least 120 days after the last treatment.

• For men: agreement to use contraceptive measures and agreement to refrain from donating sperm.

Exclusion Criteria:

• Other active malignant diseases requiring treatment.

• Significant medical condition per investigators judgement e.g. severe Asthma or chronic obstructive lung disease (COLD), poorly regulated heart condition, insulin dependent diabetes mellitus.

• Acute or chronic viral/bacterial infection e.g. human immunodeficiency virus (HIV), Cytomegalo virus (CMV), Epstein-barr virus (EBV), hepatitis or tuberculosis

• Serious known allergies or earlier anaphylactic reactions.

• Known sensibility towards Montanide ISA51

• Any active autoimmune diseases e.g. autoimmune neutropenia, thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, scleroderma, myasthenia gravis, autoimmune glomerulonephritis, autoimmune adrenal deficiency, autoimmune thyroiditis etc.

• Pregnant and breastfeeding women.

• Fertile women not using secure contraception with a failure rate less than < 1%

• Psychiatric disorders that according to the investigator could influence compliance.

• Treatment with other experimental drugs

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Intervention

Combination Product:
• PD-L1, PD-L2 peptides with Montanide ISA51
PD-L1: 19 amino acid sequence from the PD-L1 protein; PD-L2: 21 amino acid sequence from the PD-L2 protein; The peptides are dissolved in dimethyl sulphoxide (DMSO) and mixed with Montanide.

Locations

Country	Name	City	State
Denmark	Herlev Hospital	Herlev

Sponsors (2)

Lead Sponsor	Collaborator
Lars Møller Pedersen	IO Biotech

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical response according to IW-CLL	Progressive disease (PD), stable disease (SD), partial response (PR), complete response (CR) calculated on basis of changes in circulating lymphocytes and lymphnode/spleen/liver size according to criteria from the international working group on CLL (IW-CLL).	1 year
Secondary	Immune response by elispot	T-cell responses measured by Enzyme-linked immunospot assay (ELISpot) counting the number of spots with cytokine release.	1 year
Secondary	Grades of adverse events (AE)	Registered according to common terminology criteria for adverse events (CTCAE) v4.03. Each AE will be Graded I-V.	1 year